Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now full pipeline

Hypercholesterolemia: full-pipeline trial registry

5 of 63 indexed Hypercholesterolemia trials are currently recruiting.

Corpus placement: #222 of 28,707 conditions by registered trial count.

63 US clinical trials · 5 currently recruiting · #222 of 28,707 conditions by registered trial count

Hypercholesterolemia: 63 US clinical trials tracked, 5 recruiting.

Hypercholesterolemia is the subject of 63 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 26 are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis, running 4 of these trials.

Enrollment posture brief

Registry condition hypercholesterolemia

OPEN 5 | RECR 8% | LATE 26 | EARLY 18 | RANK #222 | SPON 4

Nearest open-share peer: Sinusitis (8% recruiting · 13 trials)

Hematopoietic and Lymphatic 76.2%Mental Health54%Pancreatic Adenocarcinoma49.2%Delirium38.1%Hypercholesterolemia (this)8%
Open-enrollment share among volume-matched conditions near Hypercholesterolemia

Hypercholesterolemia lists 5 open slots (8% of 63 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hypercholesterolemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hypercholesterolemia is recruiting below its size-band peers.

    5 of 63 indexed trials (7.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Hypercholesterolemia trials is spread across many organizations.

    Novartis accounts for 4 of 63 trials (6.3%). 41 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hypercholesterolemia enrolment sits around 143 participants.

    Median target enrolment is 143 among the 63 trials that report a genuine target (sentinel values excluded). 24 of those (38.1%) plan for fewer than 100 participants.

  4. Hypercholesterolemia research is mostly interventional.

    56 interventional and 7 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 18Phase 210Phase 318Phase 48

Open and recent trials

63 total, page 2 of 2

COMPLETED Phase 2 60 participants

The Safety & Efficacy of Combination BMS-201038 (AEGR-733) & Ezetimibe vs. Monotherapy in Moderate Hypercholesterolemia

Aegerion Pharmaceuticals

NCT00405067

COMPLETED NA 60 participants

Low Fat Vegan or American Heart Association Diets & Cardiovascular Risk in Obese 9-18 y.o. With Elevated Cholesterol

The Cleveland Clinic

NCT01817491

COMPLETED Phase 2 58 participants

Open-Label Extension of Study R727-CL-1003 (NCT01266876) to Evaluate the Long-Term Safety and Efficacy of Alirocumab (REGN727) in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

Regeneron Pharmaceuticals

NCT01576484

COMPLETED NA 57 participants

Effect of Diabetes Mellitus on Cholesterol Metabolism

Medical College of Wisconsin

NCT00879710

COMPLETED Phase 1 43 participants

Pilot Program to Improve Statin Adherence and Lower Cholesterol in Older Adults

University of Missouri-Columbia

NCT01227330

COMPLETED Phase 2 36 participants

Effect of Statins on Oxidative Stress and Endothelial Progenitor Cells

Emory University

NCT00166036

COMPLETED Phase 4 34 participants

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

Bronx VA Medical Center

NCT00762164

COMPLETED Phase 2 32 participants

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

LIB Therapeutics

NCT03847974

COMPLETED NA 30 participants

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00046267

COMPLETED NA 22 participants

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS

Beth Israel Deaconess Medical Center

NCT01702987

COMPLETED 19 participants

Using Nudges to Implement Comparative Effectiveness

NYU Langone Health

NCT01575171

COMPLETED Phase 1 13 participants

A Study of LY3015014 in Healthy Participants With High Cholesterol

Eli Lilly and Company

NCT01671085

COMPLETED NA 10 participants

Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans

USDA, Western Human Nutrition Research Center

NCT02011789

← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 8
Phase 2 10
Phase 3 18
Phase 4 8

Named interventions

Most-linked intervention names on Hypercholesterolemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
7 trials
Ezetimibe Drug
6 trials
Alirocumab Drug
5 trials
Placebo (for alirocumab) Drug
3 trials
Lipid-Modifying Therapy (LMT) Drug
3 trials
Enlicitide Decanoate Drug
3 trials
Simvastatin Drug
3 trials
ETC-1002 Drug
2 trials

US sites by state

Facility locations filed on Hypercholesterolemia trials. A trial with sites in several states counts in each.

Florida 25 trials
California 22 trials
Alabama 15 trials
Ohio 12 trials
Illinois 12 trials
North Carolina 11 trials
Indiana 10 trials
Arizona 10 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hypercholesterolemia page

63 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Hypercholesterolemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Novartis sponsors the most Hypercholesterolemia trials on record, review their full trial history before evaluating a specific study. See Novartis's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypercholesterolemia condition card totals 63 registered trials; most-linked intervention Placebo; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.